LynkDose LynkDose
Metabolic Long-acting amylin analog

Cagrilintide

Also known as: AM833 · Amylin analog

A long-acting amylin analog discussed in the context of appetite regulation and weight management, often paired with GLP-1 agonists.

Class

Long-acting amylin analog

Default unit

mg

Common route

Subcutaneous

Typical half-life

~6–8 days

Frequency

Once weekly

Commonly associated areas

Illustrative map of the body systems Cagrilintide is most often discussed in relation to. Relative emphasis only — not a measure of efficacy or a medical claim.

Appetite regulation 92
Satiety signaling 85
Body weight 80
Gastric emptying (slows) 65
Cravings & food noise 60
Cardiometabolic markers 40

Proposed mechanisms / pathways

Amylin receptor agonism Calcitonin-receptor signaling Satiety / appetite signaling Slowed gastric emptying

What is Cagrilintide?

Cagrilintide is a long-acting amylin analog — an engineered peptide modeled on amylin, a hormone the pancreas co-secretes with insulin after a meal. It is studied in the context of appetite and weight management, and is most often discussed as a partner to GLP-1 agonists rather than on its own. Its long-acting design is associated with a once-weekly cadence.

How it is thought to work

Amylin analogs are thought to act on amylin and calcitonin receptors in regions of the brain involved in satiety. The proposed effect is to reinforce feelings of fullness and slow gastric emptying, which is reported to reduce food intake. Because amylin and GLP-1 work through different pathways, cagrilintide is often described as complementary to GLP-1 agonists — the rationale behind combinations such as CagriSema. These mechanisms are still being characterized.

Educational only — not medical advice

Cagrilintide is an investigational compound that is not approved for general human use, and this page is educational rather than a recommendation or dose. Consult a qualified healthcare provider before considering anything described here.

Tracking Cagrilintide in LynkDose

Because cagrilintide is long-acting and frequently titrated, record-keeping is where it pays off: log each weekly dose with its date, note any dose changes, do a consistent weekly weigh-in, and track appetite, fullness, and any side effects. If it is paired with a GLP-1 agonist, logging both in LynkDose makes it far easier to see which change lines up with a stall, a plateau, or a shift in how you feel.

Commonly discussed for

  • Appetite and satiety regulation
  • Weight-management protocols
  • Combination use with GLP-1 agonists

Often stacked: Frequently discussed alongside semaglutide (the CagriSema combination) and other GLP-1 agonists in dual-mechanism appetite protocols.

How to track Cagrilintide in LynkDose

Like many long-acting metabolic compounds, cagrilintide is often titrated upward over weeks — logging each weekly dose with its date, plus a consistent weigh-in and appetite notes, lets you tie changes to a specific step.

Deeper read: Tracking GLP-1 Peptides (Semaglutide & Tirzepatide)

Not medical advice

This page is educational and does not recommend, prescribe, or dose any compound. Many peptides are research chemicals not approved for general human use. Always consult a qualified healthcare provider and follow the laws in your area.

Related peptides